Are cell-based therapies for kidney disease safe? A systematic review of preclinical evidence
In conclusion, for benign cell-based therapies, well-designed pre-clinical studies, including all control groups required and good manufacturing processes securing safety, need to be done early in development. Preferably, this should be performed side by side with efficacy evaluation and according to the official guidelines of leading health organizations.
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Kidney Disease | Drugs & Pharmacology | Genetics | Microbiology | Study | Urology & Nephrology